HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on BioLine Rx (NASDAQ:BLRX) and maintains a $21 price target.
February 29, 2024 | 8:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on BioLine Rx and maintains a $21 price target.
The reiteration of a Buy rating and maintenance of a $21 price target by a reputable analyst like Joseph Pantginis suggests a strong bullish sentiment towards BioLine Rx. This endorsement is likely to instill confidence in investors and could lead to a positive short-term impact on BLRX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100